Abstract
Objectives Although the National Early Warning Score (NEWS) and its latest version NEWS2 are recommended for monitoring for deterioration in patients admitted to hospital, little is known about their performance in COVID-19 patients. We aimed to compare the performance of the NEWS and NEWS2 in patients with COVID-19 versus those without during the first phase of the pandemic.
Design a retrospective cross-sectional study
Setting Two acute hospitals (Scarborough and York) are combined into a single dataset and analysed collectively.
Participants Adult (>=18 years) non-elective admissions discharged between 11-March-2020 to 13-June-2020 with an index or on-admission NEWS2 electronically recorded within ±24 hours of admission are used to predict mortality at four-time points (in-hospital, 24hours, 48hours, and 72hours) in COVID-19 versus non-COVID-19 admissions.
Results Out of 6480 non-elective admissions, 620 (9.6%) had a diagnosis of COVID-19. They were older (73.3 vs 67.7yrs), more often male (54.7% vs 50.1%), had higher index NEWS (4 vs 2.5) and NEWS2 (4.6 vs 2.8) scores and higher in-hospital mortality (32.1% vs 5.8%). The c-statistics for predicting in-hospital mortality in COVID-19 admissions was significantly lower using NEWS (0.64 vs 0.74) or NEWS2 (0.64 vs 0.74), however these differences reduced at 72hours (NEWS: 0.75 vs 0.81; NEWS2: 0.71 vs 0.81), 48 hours (NEWS: 0.78 vs 0.81; NEWS2: 0.76 vs 0.82) and 24hours (NEWS: 0.84 vs 0.84; NEWS2: 0.86 vs 0.84). Increasing NEWS2 values reflected increased mortality, but for any given value the absolute risk was on average 24% higher (e.g., NEWS2=5: 36% vs 9%).
Conclusions The index or on-admission NEWS and NEWS2 offer lower discrimination for COVID-19 admissions versus non-COVID-19 admissions. The index NEWS2 is not better than the index NEWS. For each value of the index NEWS or index NEWS2, COVID-19 admissions had a substantially higher risk of mortality than non-COVID-19 admissions which reflects the increased baseline mortality risk of COVID-19.
Article Summary
This study data is from a single NHS Trust and used the index NEWS/NEWS2 scores. The extent to which these findings are generalisable, especially to minority ethnic groups with higher mortality, needs further study.
Although we found no evidence of NEWS2 as having a superior performance to NEWS, this does suggest that the additional enhancements in NEWS2 are having a limited impact and the underlying reasons need further study.
NEWS and NEWS2 are repeatedly updated for each patient according to local hospital protocols, and the extent to which changes in NEWS or NEWS2 over time reflect changes in mortality risk needs further study.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the Health Foundation. The Health Foundation is an independent charity working to improve the quality of health care in the UK. This research was supported by the National Institute for Health Research (NIHR) Yorkshire and Humberside Patient Safety Translational Research Centre (NIHR YHPSTRC). The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was deemed to be exempt from ethical approval because it was classified as an evaluation. Furthermore, this study used already de-identified data from an ongoing study involving NEWS which received ethical approval from Health Research Authority (HRA) and Health and Care Research Wales (HCRW) (reference number 19/HRA/0548).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail: drichardson{at}doctors.org.uk
E-mail: M.Faisal1{at}bradford.ac.uk
E-mail: massimo.fiori{at}york.nhs.uk
E-mail: Kevin.Beatson{at}York.NHS.uk
E-mail: M.A.Mohammed5{at}Bradford.ac.uk
Data Availability
Our data sharing agreement with NHS York hospital trust does not permit us to share this data with other parties. Nonetheless if anyone is interested in the data, then they should contact the R&D offices in the first instance.